Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...
Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...
Shanghai Healthcare Administration Pushes for 11th Round of VBP
Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...
Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance
Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria
France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...
Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China
US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...
Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...
Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...
Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development
China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...
Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...
Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...
Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System
US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...
Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...
AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...
Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...